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ABSTRACT The continued rise and spread of antimicrobial resistance among bacte-
rial pathogens pose a serious challenge to global health. Countering antimicrobial-
resistant pathogens requires a multifaceted effort that includes the discovery of
novel therapeutic approaches. Here, we establish the capacity of the human CXC
chemokines CXCL9 and CXCL10 to kill multidrug-resistant Gram-negative bacteria,
including New Delhi metallo-beta-lactamase-1-producing Klebsiella pneumoniae and
colistin-resistant members of the family Enterobacteriaceae that harbor the mobile
colistin resistance protein MCR-1 and thus possess phosphoethanolamine-modiﬁed
lipid A. Colistin-resistant K. pneumoniae isolates affected by genetic mutation of the
PmrA/PmrB two-component system, a chromosomally encoded regulator of lipopoly-
saccharide modiﬁcation, and containing 4-amino-4-deoxy-L-arabinose-modiﬁed lipid
A were also found to be susceptible to chemokine-mediated antimicrobial activity.
However, loss of PhoP/PhoQ autoregulatory control, caused by disruption of the
gene encoding the negative regulator MgrB, limited the bactericidal effects of
CXCL9 and CXCL10 in a variable, strain-speciﬁc manner. Cumulatively, these ﬁnd-
ings provide mechanistic insight into chemokine-mediated antimicrobial activity,
highlight disparities amongst determinants of colistin resistance, and suggest that
chemokine-mediated bactericidal effects merit additional investigation as a thera-
peutic avenue for treating infections caused by multidrug-resistant pathogens.
IMPORTANCE As bacterial pathogens become resistant to multiple antibiotics, the
infections they cause become increasingly difﬁcult to treat. Carbapenem antibiotics
provide an essential clinical barrier against multidrug-resistant bacteria; however, the
dissemination of bacterial enzymes capable of inactivating carbapenems threatens
the utility of these important antibiotics. Compounding this concern is the global
spread of bacteria invulnerable to colistin, a polymyxin antibiotic considered to be a
last line of defense against carbapenem-resistant pathogens. As the effectiveness of
existing antibiotics erodes, it is critical to develop innovative antimicrobial therapies.
To this end, we demonstrate that the chemokines CXCL9 and CXCL10 kill the most
concerning carbapenem- and colistin-resistant pathogens. Our ﬁndings provide a
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unique and timely foundation for therapeutic strategies capable of countering
antibiotic-resistant “superbugs.”
KEYWORDS Gram negative, antimicrobial resistance, carbapenem, chemokine,
colistin
Antimicrobial-resistant bacterial pathogens are a serious threat to global health.Infections caused by multidrug-resistant (MDR) organisms have limited therapeutic
options, resulting in frequent treatment failures and increased mortality rates (1).
Carbapenem antibiotics have provided a clinical barrier against MDR Gram-negative
pathogens; however, the continued emergence and spread of carbapenemases,
-lactamase enzymes capable of hydrolyzing and inactivating carbapenems, imperil the
utility of these key antibiotics. Carbapenem-resistant Enterobacteriaceae (CRE), includ-
ing carbapenemase-producing Klebsiella spp. and Escherichia coli, are resistant to nearly
all classes of antibiotics. Consequently, CRE are listed by the U.S. Centers for Disease
Control and Prevention as an immediate threat to public health that requires urgent
and aggressive action (2).
The challenge posed by CRE has been countered by the use of colistin (CST), a
decades-old polymyxin regarded as a last line of defense against highly drug-resistant
Gram-negative pathogens. Unfortunately, extensive application of CST in animal hus-
bandry has provided selective pressure for the development of CST resistance. Espe-
cially concerning is the dissemination of mcr-1, a plasmid-borne determinant of poly-
myxin resistance, among human pathogens (3). CST resistance arising from genetic
alterations of chromosomal loci (e.g., mgrB and pmrB) has also been reported (4);
however, unlike mcr-1, these altered genes are not transmissible between bacterial
species. The acquisition of CST resistance by CRE highlights the emergence of exten-
sively drug-resistant “superbugs” that are invulnerable to most, and in some cases all,
available antibiotics.
The mounting human and economic burden of MDR bacteria, compounded by
steep declines in the development of new antimicrobial agents (2), underscores the
importance of developing novel therapeutic strategies. Previous work by our laboratory
and others suggests antimicrobial chemokines as one possible avenue to counter the
threat posed by antibiotic resistance (5, 6). Indeed, while best known for orchestrating
immune cell recruitment to sites of infection, a subset of chemokines has been shown
to exert antimicrobial activity against a range of microorganisms (7, 8). Here we report
that the CXC chemokines CXCL9 and CXCL10 kill MDR bacterial pathogens, including
CRE and CST-resistant clinical isolates.
RESULTS AND DISCUSSION
CXC chemokines exhibit bactericidal effects against CRE. The capacity of CXC
chemokines to directly kill CRE was examined by using clinical isolates of MDR Klebsiella
pneumoniae that possess either New Delhi metallo--lactamase-1 (NDM-1) or both
NDM-1 and oxacillinase-48 (OXA-48) carbapenemases (Fig. 1A). NDM-1 presents a
considerable challenge to antimicrobial therapy because of its high enzymatic and
genetic stability (9, 10) and exceptional horizontal mobility among Gram-negative
bacterial species (11). On the basis of prior investigations (12), CRE were treated with
48 g/ml CXCL10. Viability determinations (CFU/ml) demonstrated that CXCL10 killed
all of the MDR carbapenemase-producing organisms tested (Fig. 1B). Indeed, CXCL10-
mediated killing of CRE was greater than that of the carbapenemase-negative control
K. pneumoniae ATCC 43816. Human CXCL9 also efﬁciently killed CRE (Fig. 1C).
Chemokine-mediated antimicrobial activity against CRE was dependent on the
chemokine concentration used (Fig. 1D). The half-maximal effective concentration
(EC50) of CXCL10 for isolate BL12125 was 9.6  1.1 g/ml (~1.1 M). This value is
comparable to the previously determined bactericidal capacity of human CXCL10
against Bacillus anthracis bacilli (EC50, 0.5 M) and E. coli (EC50, 0.3 to 1.0 M) and is also
similar to those reported for the killing of K. pneumoniae by human (EC50, 0.3 M) and
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murine (EC50, 1.6 M) CCL28 (5, 12, 13). Our ﬁndings demonstrate that CXCL9 and
CXCL10 kill carbapenem-resistant bacterial isolates that also maintain broad co-
resistance against additional classes of antibiotics. Given the increasingly limited op-
tions available to treat infections caused by MDR bacterial pathogens, this novel
observation highlights the potential utility of chemokine-mediated antimicrobial activ-
ity as a foundation for developing innovative therapeutic strategies to counter a range
of antibiotic-resistant pathogens.
CXC chemokines mediate antimicrobial activity against mcr-1-harboring bac-
teria. CST is a cationic lipopeptide that targets Gram-negative bacteria through elec-
trostatic interactions with phosphate groups on the lipid A component of lipopolysac-
charide (14). While the genetic basis of CST resistance is diverse, the principal
mechanisms are analogous; chemical modiﬁcation of lipid A phosphates mask their
negative charge, thereby decreasing afﬁnity between CST and the bacterial cell enve-
lope (4). Most concerning among determinants of CST resistance ismcr-1, a horizontally
transmissible, plasmid-borne gene that encodes a phosphoethanolamine (pEtN) trans-
ferase that catalyzes the addition of pEtN onto phosphate moieties of lipid A (3). MCR-1
has been shown to reduce CST susceptibility in a number of important human
pathogens, including E. coli, K. pneumoniae, Pseudomonas aeruginosa, and Acinetobacter
baumannii (15).
To deﬁne the capacity of CXCL9 and CXCL10 to kill mcr-1 CST-resistant bacteria,
three E. coli isolates were used, FI-4531, an mcr-1 clinical isolate; J53, a laboratory
reference strain; and J53 mcr-1, a J53 transconjugant carrying the mcr-1-containing
plasmid from FI-4531. The CST resistance of mcr-1 isolates was conﬁrmed using a
modiﬁed Etest (Fig. 2A). To verify the presence or absence of pEtN-modiﬁed lipid A in
the outer membrane of the above bacterial strains (Fig. 2B; see Fig. S1 in the supple-
FIG 1 Bactericidal effects of CXC chemokines against CRE. (A) Carbapenem-resistant K. pneumoniae isolates and a species-matched control (ATCC 43816) are
shown. Multilocus sequence types (MLSTs) and genes encoding the NDM-1 and/or OXA-48 carbapenemases are indicated. Antimicrobial susceptibilities
(reported as MIC [g/ml]) were interpreted as resistant (red) or susceptible (green) in accordance with established breakpoints. The antibiotics tested were
ampicillin (AMP), amoxicillin-clavulanic acid (AMC), AMP-sulbactam (SAM), piperacillin-tazobactam (TZP), cefazolin (CFZ), cefoxitin (FOX), cefotaxime (CTX),
ceftriaxone (CRO), aztreonam (ATM), cefepime (FEP), ertapenem (ERT), doripenem (DOR), imipenem (IPM), meropenem (MEM), CST, amikacin (AMK), gentamicin
(GEN), tobramycin (TOB), ciproﬂoxacin (CIP), levoﬂoxacin (LVX), tetracycline (TET), tigecycline (TGC), and trimethoprim-sulfamethoxazole (SXT). Bacteria were
treated with 48 g/ml CXCL10 (B) or CXCL9 (C), and survival was measured by CFU determination (limit of detection, 500 CFU/ml; n.d., none detected). Data
are expressed as percentages of the respective untreated-control value and represent the mean  the standard error of the mean (n  3). *, P  0.05; **, P 
0.01 (compared to ATCC 43816). (D) CRE isolate BL12125 was treated with increasing concentrations of CXCL10. Data are expressed as percentages of the
untreated-control value and represent the mean  the standard error of the mean (n  3). ***, P  0.001 (compared to the untreated control).
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mental material), lipid extracts from each were prepared and analyzed by matrix-
assisted laser desorption/ionization time-of-ﬂight (MALDI-TOF) mass spectrometry
(Fig. 2C). The canonical, unmodiﬁed bis-phosphorylated hexa-acylated base peak was
observed in all mass spectra and was the only major ion detected for J53. In addition
to the base peak, both FI-4531 and J53 mcr-1 displayed major ions corresponding to
pEtN-modiﬁed lipid A. Thus, the CST resistance of mcr-1 strains was appropriately
associated with pEtN-modiﬁed lipid A.
Exposure of FI-4531, J53, or J53 mcr-1 to 4.0 g/ml human CXCL10 resulted in
approximately 2-log killing, as measured by CFU determination, without regard to
mcr-1 status (Fig. 2D). Treatment with 12.0 g/ml CXCL10 consistently resulted in the
death of the initial inoculum of each E. coli strain below the level of detection
(500 CFU/ml). CXCL9 was also observed to mediate similar, marked bactericidal effects
FIG 2 Chemokine-mediated antimicrobial activity against mcr-1 bacteria. (A) CST susceptibility testing of E. coli by modiﬁed Etest. CST concentrations are in
g/ml. Images are representative of two or three separate tests. Printed CO indicates a CST test strip. (B) Molecular structures and mass-to-charge (m/z) ratios
of signature ions identiﬁed in E. coli mass spectra. (C) Lipid extracts were analyzed by MALDI-TOF mass spectrometry. The unmodiﬁed base peak (m/z 1,796)
was observed in all spectra. Major ions at m/z 1,919 and 1,839, corresponding to pEtN-modiﬁed lipid A and pEtN-modiﬁed lipid A lacking the second phosphate
moiety, were detected only in spectra generated from mcr-1 isolates. E. coli isolates were treated with 4 or 12 g/ml CXCL10 (D) or CXCL9 (E); K. pneumoniae
strains were treated with 48 g/ml CXCL10 (F). Different chemokine concentrations were assayed on the basis of the inherent susceptibilities of these organisms.
Survival was measured by CFU determination (limit of detection, 500 CFU/ml; n.d., none detected). Data are expressed as percentages of the respective
untreated-control value and represent the mean  the standard error of the mean (n  3). ns, not signiﬁcant.
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against the E. coli strains examined (Fig. 2E). Furthermore, introduction of a mcr-1-
carrying recombinant plasmid into CST-susceptible K. pneumoniae ATCC 13883 did not
promote resistance to chemokine-mediated antimicrobial activity (Fig. 2F), despite
conferring CST resistance (MIC, 32 g/ml) (15). These data demonstrate that CXCL9 and
CXCL10 are able to effectively kill mcr-1 CST-resistant pathogens that maintain
pEtN-modiﬁed lipid A in their outer membrane.
Disparate chromosomal determinants of CST resistance differentially impact
the bactericidal activity of CXC chemokines. Similar to pEtN, the modiﬁcation of lipid
A with 4-amino-4-deoxy-L-arabinose (L-Ara4N) reduces the net charge of the bacterial
cell envelope, thereby promoting CST resistance. The PmrA/PmrB two-component
regulatory system governs the expression of chromosomal loci that encode the en-
zymes responsible for L-Ara4N synthesis and incorporation into lipid A (16). Discrete,
nonsynonymous mutations in pmrA or pmrB are associated with the constitutive
activation of this signaling pathway and CST resistance (4). Particular mutations in
PhoP/PhoQ, an upstream activator of the response regulator PmrA (17), and genetic
disruption of MgrB, a negative regulator of PhoP/PhoQ signaling (18), also result in the
activation of PmrA and CST-resistant phenotypes (4, 19). While not horizontally trans-
missible, these determinants have been identiﬁed in a number of human pathogens
and present an emergent clinical challenge (19).
To test the effects of chromosomal determinants of CST resistance on chemokine-
mediated antimicrobial activity, we examined MDR, mcr-1 negative, CST-resistant
K. pneumoniae clinical isolates (Fig. 3A). Bacteria were treated with 48 g/ml CXCL10,
and survival was measured by CFU determination (Fig. 3B). Curiously, CXCL10 exhibited
strain-speciﬁc bactericidal activity against the isolates examined, i.e., three susceptible
FIG 3 Effects of chromosomal determinants of CST resistance on the bactericidal activity of CXC chemokines. (A) MLSTs, carbapenemase genes, and
antimicrobial susceptibilities of CST-resistant K. pneumoniae isolates are shown. MICs [g/ml] were interpreted as resistant (red), intermediate (yellow), or
susceptible (green) on the basis of established breakpoints. For deﬁnitions of abbreviations, see the legend to Fig. 1. Bacteria were treated with 48 g/ml
CXCL10 (B) or CXCL9 (C), and survival was measured by CFU determination. Data are expressed as percentages of the respective untreated-control value and
represent the mean the standard error of the mean (n 3). **, P 0.01; ***, P 0.001; ns, not signiﬁcant (compared to ATCC 43816 [panel B] or the untreated
control [panel C]). (D) Visualization of mgrB amplicons generated by PCR from the isolates indicated. Amplicon size of intact K. pneumoniae mgrB, 235 bp.
Markers indicate 1,000 and 200 bp.
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isolates (25% survival; BA2664, BL8800, and BA2880), three intermediate isolates (25
to 75% survival; MS84, BA3783, and BU19801), and one unaffected isolate (BL849). The
intermediate phenotype displayed by isolate MS84 was also observed upon treatment
with CXCL9 (Fig. 3C). MALDI-TOF analysis demonstrated that all of the bacterial isolates
examined possessed similar relative amounts of L-Ara4N-modiﬁed lipid A in their outer
membrane (Fig. S2); thus, the reduction in anionic surface charge afforded by L-Ara4N
modiﬁcation of lipid A does not appear to explain the differences in susceptibility to
chemokine-mediated antimicrobial activity. This observation is consistent with our
ﬁnding that pEtN modiﬁcation of lipid A also does not reduce susceptibility to CXCL9
or CXCL10. Taken together, these results support the notion that CXCL9 and CXCL10 kill
bacterial pathogens via a mechanism distinct, at least in part, from those reliant upon
electrostatic interaction as proposed for a number of cationic antimicrobial peptides,
including CST.
We next examined the possibility that disparate chromosomal determinants con-
ferring CST resistance account for the noted variability in CXCL10 susceptibility. To
identify the speciﬁc mutations/disruptions that underlie CST resistance in the above
clinical isolates, ﬁve loci (mgrB, pmrA, pmrB, phoP, and phoQ) previously reported to be
associated with CST-resistant phenotypes were examined by amplicon sequencing and
analysis of whole-genome sequence data (4, 20). All of our CST-resistant, CXCL10-
susceptible K. pneumoniae isolates (BA2664, BL8800, and BA2880) possessed a nonsyn-
onymous pmrB point mutation resulting in a Thr157Pro amino acid substitution. This
particular substitution has been proposed to impact dimerization and phosphotrans-
ferase by PmrB, leading to constitutive activation of PmrA and, consequently, CST
resistance (21). In contrast, CST-resistant organisms that exhibited partial or complete
resistance to CXCL10 were found to possessmgrB loci disrupted by insertion sequences
(MS84, IS5-like element; BA3783, IS1-like element; BU19801, ISKpn25 element) or to be
missing the mgrB gene entirely (BL849) (Fig. 3D). Functional inactivation of mgrB
eliminates the negative feedback loop governing PhoP/PhoQ signaling, resulting in
both direct and indirect (via PmrD-dependent activation of PmrA) transcriptional
activation of the biosynthetic machinery necessary for L-Ara4N modiﬁcation of lipid A
in K. pneumoniae (4, 22). No isolates were found to have genetic aberrations previously
associated with CST resistance in the pmrA, phoP, or phoQ loci.
That impairment of PhoP/PhoQ autoregulatory control curtails the antimicrobial
activity of CXCL10, but direct disruption of PmrA/PmrB does not, reasonably suggests
that disparate chromosomal determinants of CST resistance inequitably affect CXCL10
susceptibility. Indeed, while constitutive activation of PmrA, either directly or indirectly,
would be expected to result in the incorporation of L-Ara4N-modiﬁed lipid A into the
bacterial outer membrane, disruption of PhoP/PhoQ autoregulation would also be
expected to inﬂuence the expression and/or activity of a number of additional enzymes
and regulatory systems central to defensive alteration of the bacterial outer membrane
(23). These ﬁndings highlight the underappreciated prospect that distinct chromosomal
determinants of CST resistance differentially impact outer membrane physiology and
thus variably affect microbial traits beyond CST resistance.
Restoration of PhoP/PhoQ autoregulatory control abolishes protection from
CXCL10. To substantiate that mgrB disruption and the resultant loss of PhoP/PhoQ
autoregulation account for reduced CXCL10 susceptibility, we performed genetic com-
plementation and susceptibility determination. For these experiments, native K. pneu-
moniae mgrB was introduced into isolate MS84. This MDR isolate was chosen for mgrB
complementation since it demonstrated reduced CXCL10 susceptibility yet was still
susceptible to TET and thus amenable to screening selection.
Complementation of isolate MS84 with pACYC::mgrB restored CST susceptibility
(Fig. 4A), elicited the loss of L-Ara4N-modiﬁed lipid A (Fig. 4B and C), and markedly
increased susceptibility to CXCL10 (Fig. 4D). In contrast, the empty-vector control was
equivalent to the MS84 parent strain in all of the regards examined. These data were
validated by using an additional set of three K. pneumoniae isolates, KKBO1, KKBO4, and
KKBO4 mgrB. KKBO1 and KKBO4 are sequentially collected, K. pneumoniae carbapen-
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emase (KPC)-producing clinical isolates that are CST susceptible or resistant, respec-
tively. The CST resistance of KKBO4 has previously been shown to be caused by
insertional inactivation of mgrB (24). Genetic complementation with pACYC::mgrB
reestablished CST susceptibility in KKBO4 (Fig. 4E) and eliminated L-Ara4N-modiﬁed
lipid A (Fig. S2). Determination of chemokine susceptibility demonstrated that only
K. pneumoniae isolates harboring intact mgrB alleles were fully sensitive to the bacte-
ricidal effects of CXCL10 (Fig. 4F). These observations demonstrate that diminished
CXCL10 susceptibility is associated with the functional inactivation of mgrB.
A pair of additional observations can be made from the lipid A mass spectra
presented in this work. In K. pneumoniae, the PhoP/PhoQ-activated loci lpxO and pagP
encode lipid A-modifying enzymes responsible for the hydroxylation of 2=-linked
FIG 4 Effect of mgrB complementation on resistance phenotypes. (A) CST susceptibility testing of K. pneumoniae strains by modiﬁed E test. CST concentrations
are in g/ml. Images are representative of three separate tests. (B) Molecular structures andm/z values of selected ions identiﬁed in K. pneumoniaemass spectra.
(C) MALDI-TOF analysis demonstrated the canonical K. pneumoniae lipid A base peak (m/z 1,824). Major ions at 1,955 (m/z 1,824  L-Ara4N), 1,971 (m/z 1,840
 L-Ara4N), and 1,891 (m/z 1,971  PO3) were observed in mass spectra from strains harboring disrupted mgrB. Additional ions observed at m/z 1,840, 2,063,
and 2,079 are indicative of lipid A hydroxylation, palmitoylation, or both, respectively. (D) Bacteria were treated with 48 g/ml CXCL10. Survival was measured
by CFU counting (limit of detection, 500 CFU/ml; n.d., none detected). Data are expressed as percentages of the respective untreated-control value and
represent the mean the standard error of the mean (n 3). (E) CST susceptibility testing by modiﬁed E test. Images are representative of two or three separate
tests. (F) Bacteria were treated with 48 g/ml CXCL10. Survival was measured by CFU counting (limit of detection, 500 CFU/ml; n.d., none detected). Data are
expressed as percentages of the respective untreated control and represent the mean  the standard error of the mean (n  3).
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myristate (LpxO) and the addition of palmitate (C16:0) onto the hydroxyl group of
hydroxymyristate (PagP) (25). The reinforcement of hydrogen bond networks by hy-
droxylated lipid A and the strengthening of hydrophobic interactions by palmitoylated
lipid A are proposed to fortify outer membrane barrier function and impede penetra-
tion by antimicrobial peptides. Although hydroxylation and palmitoylation of lipid A
have each been reported to promote bacterial resistance to antimicrobial peptides (26,
27), the presence of these PhoP/PhoQ-regulated modiﬁcations did not appear to
account for CXCL10 resistance in isolates harboring disruptions inmgrB. This conclusion
is evidenced by the detection of 2-hydroxylated lipid A (12/12 isolates) and palmitoy-
lated lipid A (6/12 isolates) in both CXCL10-susceptible and -resistant K. pneumoniae
strains (Fig. 4; Fig. S2).
Further investigation is required to clarify the molecular basis of PhoP/PhoQ-
dependent protection from the bactericidal effects of CXCL9 and CXCL10 and to
determine whether this limitation can be overcome. Of interest, K. pneumoniae isolate
BU19801 demonstrated mgrB disruption yet was only marginally resistant to CXCL10
(Fig. 3). This phenotype is distinct from the pronounced CXCL10 resistance exhibited by
other clinical isolates harboring interrupted mgrB and may provide an opportunity to
elucidate the molecular basis of protection from CXCL10.
While it is unknown whether antimicrobial chemokines act through a common
mechanism, they are generally considered to target bacteria via electrostatic interac-
tions between positively charged topological “patches” present on the chemokine and
negatively charged constituents of the bacterial cell envelope, notably, the lipid A
component of lipopolysaccharide in Gram-negative bacteria (7, 28). This basic mecha-
nism is analogous to those proposed for a number of cationic antimicrobial peptides,
including CST, and is in agreement with many experimental results (6, 29). However,
pEtN or L-Ara4N modiﬁcation of lipid A phosphate moieties and consequent reduction
of the bacterial surface charge were not found to speciﬁcally diminish the bactericidal
effects of CXCL9 and CXCL10. These ﬁndings suggest that factors other than charge-
based interactions may be critical for the bactericidal action of these CXC chemokines.
This notion is supported by previous ﬁndings that CXCL10 may interact directly with
the conserved bacterial component FtsX, which displays homology with CXCR3, the
cognate cellular receptor of CXCL10 (30, 31). Elucidation of the underlying principles of
chemokine-mediated antimicrobial activity will inform the development of innovative
strategies for treating infections caused by antimicrobial-resistant pathogens.
MATERIALS AND METHODS
Bacterial strains and culture conditions. The bacterial isolates used in this study and their
derivatives are summarized in Table 1. MDR K. pneumoniae clinical isolates BL849 (CFSAN044563),
BU19801 (CFSAN044564), MS84 (CFSAN044565), BL12125 (CFSAN044566), BL12456 (CFSAN044568),
BA3783 (CFSAN044569), BL13802 (CFSAN044570), BA2664 (CFSAN044571), BL8800 (CFSAN044572), and
BA2880 (CFSAN044573) were obtained in Pakistan (20). K. pneumoniae ATCC 43816 was used as a
species-matched control for phenotypic assays. Sequence typing of the above isolates was performed
and assignments were made in accordance with the Institut Pasteur K. pneumoniae multilocus sequence
typing scheme (http://bigsdb.pasteur.fr/). K. pneumoniae KKBO1 and KKBO4 (24), and E. coli FI-4531 were
obtained in Italy (32). E. coli J53 and K. pneumoniae ATCC 13883 were used as host backgrounds for
mcr-1-containing plasmids. E. coli DH5 was used as an intermediate in molecular cloning. Positive
control strains for antimicrobial susceptibility testing included Staphylococcus aureus ATCC 29213,
Enterococcus faecalis ATCC 29212, E. coli ATCC 25922, and P. aeruginosa ATCC 27853. Unless otherwise
noted, bacteria were cultured in Luria-Bertani (LB) medium at 37°C with continuous shaking. E. coli
FI-4531 and J53 mcr-1 were grown in the presence of 1 g/ml CST freshly prepared. K. pneumoniae MS84
derivatives and KKBO4 mgrB, each harboring pACYC constructs, were grown in the presence of 25 g/ml
TET. K. pneumoniae strains derived from ATCC 13883 and containing pBCSK constructs were grown in the
presence of 50 g/ml chloramphenicol.
Antimicrobial susceptibility testing and carbapenemase gene detection. Antimicrobial resis-
tance was ﬁrst established with the Vitek 2 system (BioMérieux, Marcy l’Etoile, France). Broth microdi-
lution, in accordance with Clinical and Laboratory Standards Institute (CLSI) guidelines (33), was subse-
quently used to determine the MICs of antibiotics representing the main families of antimicrobial agents,
i.e., ampicillin, amoxicillin-clavulanic acid, AMP-sulbactam, piperacillin-tazobactam, cefazolin, cefoxitin,
cefotaxime, ceftriaxone, aztreonam, cefepime, ertapenem, doripenem, imipenem, meropenem, CST,
amikacin, gentamicin, tobramycin, ciproﬂoxacin, levoﬂoxacin, TET, TGC, and trimethoprim-sulfa-
methoxazole. Antimicrobial susceptibilities were interpreted on the basis of 2016 CLSI breakpoints (34),
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except those for CST and TGC, which are not deﬁned by the CLSI. The European Committee for
Antimicrobial Susceptibility Testing (EUCAST) breakpoints were used for CST and TGC (35). The presence
of genes encoding the NDM-1 and OXA-48 carbapenemases was determined by PCR ampliﬁcation (36).
CST Etest.While CST resistance was established by broth microdilution, the maintenance of resistant
phenotypes was conﬁrmed with a modiﬁed Etest. Standardized inocula were prepared by diluting
overnight cultures 1:35 (vol/vol) in sterile LB broth and incubating them at 37°C with shaking. When an
optical density at 600 nm (OD600) of 0.6 was reached, a 1.5-ml volume was removed and centrifuged at
16,000 relative centrifugal force for 1 min. The supernatant was discarded, and 7 l of wet pellet was
transferred into 5 ml of 0.9% sterile saline in a 15-ml glass tube. The suspensions were adjusted to a
bacterial concentration equivalent to a 1.0 McFarland turbidity standard and inoculated onto LB agar
with sterile polyester-tipped swabs. Plates were allowed to dry for 10 min prior to the application of CST
Etest strips (BioMérieux). Sample plates were imaged after 20 h of incubation at 37°C. K. pneumoniae Etest
results not presented here are included in Fig. S3.
Chemokine treatment. Recombinant human CXCL9 and CXCL10 were purchased from PeproTech
(Rocky Hill, NJ) and reconstituted at 1 mg/ml in distilled water containing 0.3% human serum albumin.
Overnight bacterial cultures were used to inoculate sterile LB medium at an OD600 of 0.1 to 0.2.
Subcultures were incubated at 37°C with continuous shaking until an OD600 of 0.6 was attained. Bacteria
were then diluted to a concentration of 3  106 CFU/ml in 10 mM potassium phosphate buffer (pH 7.4)
supplemented with 1% trypticase soy broth and treated with the chemokine indicated or an equal
volume of 0.3% human serum albumin (untreated control) in the wells of a 96-cluster plate (12). After 2
h of incubation at 37°C, serial dilutions were prepared and inoculated onto LB agar plates that were
incubated overnight at room temperature prior to colony enumeration.
Lipid A isolation from whole cells. Membrane lipids were extracted, and lipid A isolated, by an
optimized small-scale hot ammonium isobutyrate-based protocol (37). Brieﬂy, bacteria were streaked
onto LB agar to obtain individual colonies. From these colonies, cultures were prepared in 5 ml of LB
medium. Following overnight incubation at 37°C with continuous shaking, bacteria were harvested by
centrifugation (4,000 relative centrifugal force for 10 min) and pellets were treated with a 5:3 mixture of
70% (vol/vol) isobutyric acid and 1 M ammonium hydroxide (400-l total volume). Samples were then
incubated at 100°C for 30 to 45 min. After centrifugation (2,000 relative centrifugal force for 15 min) to
remove cell debris, the supernatants were transferred to fresh tubes, combined in a 1:1 ratio of distilled
water, frozen on dry ice, and lyophilized overnight. The resulting dry pellets contained whole-cell extracts
of membrane lipids.
MALDI-TOF mass spectrometry. Dry lipid extracts were washed twice with 1 ml of methanol and
then resuspended in 200 l of a 2:1:0.25 chloroform-methanol-water solvent mixture. Aliquots of 1 l
each of norharmane matrix (10 mg/ml in 2:1 chloroform-methanol) and then analyte were spotted
directly onto stainless steel target plates in duplicate. Mass spectra were recorded in negative-ion mode
with a Bruker Microﬂex LRF MALDI-TOF mass spectrometer (Bruker Daltonics, Billerica, MA) operated in
reﬂectron mode. The instrument was equipped with a 337-nm nitrogen laser, and analyses were
performed at 39.5% global intensity. Typically, 900 laser shots were summed to acquire each spectrum
and at least three mass spectra were acquired per spot. Electrospray tuning mix (Agilent, Palo Alto, CA)
TABLE 1 Bacterial isolates used in this study
Species and isolate Relevant trait(s) Source
E. coli
FI-4531 mcr-1, CSTr 32
J53 Reference/recipient, CSTs 38
J53 mcr-1 mcr-1 transconjugant, CSTr This study
K. pneumoniae
BL12125 MDR, NDM-1, CSTs 20
BL12456 MDR, NDM-1, CSTs 20
BL13802 MDR, NDM-1, OXA-48, CSTs 20
ATCC 13883 Reference/recipient, CSTs ATCCa
ATCC 13883  vector pBCSK, CSTs 15
ATCC 13883 mcr-1 pBCSK::mcr-1, CSTr 15
MS84 MDR, NDM-1, CSTr (mgrB disruption) 20
MS84  vector pACYC, CSTr This study
MS84 mgrB pACYC::mgrB, CSTs This study
BL849 MDR, NDM-1, CSTr (mgrB disruption) 20
BA3783 MDR, NDM-1, OXA-48, CSTr (mgrB disruption) 20
BA2664 MDR, OXA-48, CSTr (pmrB Thr157Pro) 20
BU19801 MDR, NDM-1, CSTr (mgrB disruption) 20
BL8800 MDR, OXA-48, CSTr (pmrB Thr157Pro) 20
BA2880 MDR, OXA-48, CSTr (pmrB Thr157Pro) 20
KKBO1 MDR, KPC, CSTs 24
KKBO4 MDR, KPC, CSTr (mgrB disruption) 24
KKBO4 mgrB pACYC::mgrB, CSTs 24
aATCC, American Type Culture Collection, Manassas, VA, USA.
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was used for mass calibration. Data were acquired and processed with ﬂexControl and ﬂexAnalysis
version 3.4 (Bruker Daltonics Inc.). Mass spectra were smoothed by a Savitzky-Golay ﬁlter, and the
baseline was corrected with TopHat. Molecular structures andm/z values of major ions identiﬁed in E. coli
and K. pneumoniae lipid A mass spectra are presented in Fig. S1. K. pneumoniae lipid A mass spectra not
presented here are in Fig. S2.
Genetic complementation and molecular cloning. Complementation of isolate MS84 with mgrB
was accomplished as previously reported for genetic complementation in KKBO4 (24). Brieﬂy, native
mgrB and ﬂanking regions were ampliﬁed from the genomic DNA of isolate BL12125 by high-ﬁdelity PCR
with primers AvaI_mgrB_F1 (5=-GACTAGCTCGGGAACACGTTTTGAAACAAGTCGATGATTC-3=) and Eco-
RI_mgrB_R1 (5=-CTAGTCGAATTCCACCACCTCAAAGAGAAGGCGTTC-3=). PCR mixtures were prepared with
Phusion DNA polymerase and incubated at 98°C for 30 s prior to 32 cycles of 98°C for 10 s, 62°C for 15 s,
and 72°C for 20 s, followed by a ﬁnal extension at 72°C for 7 min. The mgrB amplicon was puriﬁed with
the MinElute PCR puriﬁcation kit (Qiagen, Hilden, Germany) and sequence veriﬁed. The mgrB insert was
cloned into pACYC184 (New England Biolabs, Ipswich, MA) following double restriction digestion of each
with AvaI and EcoRI-HF, and ligation with T4 DNA ligase. The resulting construct, pACYC::mgrB, was
electroporated into E. coli DH5. Following sequence validation, pACYC::mgrB was transformed into
freshly prepared, electrocompetent MS84 cells (1.8 kV, 200 , 25 F). An empty-vector control strain was
also generated by transformation.
The introduction of mcr-1 from isolate FI-4531 into E. coli J53 (F met pro Azir [azide resistant]) was
accomplished by conjugation at a donor/recipient ratio of 1:10 (38). Bacteria were incubated at 35°C for
16 h, and transconjugants were selected on Mueller-Hinton agar supplemented with CST (2 g/ml) and
sodium azide (150 g/ml). Transfer of the mcr-1 resistance determinant was conﬁrmed by PCR. For mcr-1
expression by K. pneumoniae ATCC 13883, themcr-1 gene and its native promoter were ampliﬁed by PCR
and cloned into pBCSK. The generation of ATCC 13883 harboring pBCSK::mcr-1 or the empty vector alone
has been described previously (15).
Examination of chromosomal loci associated with CST resistance. PCR ampliﬁcation of chromo-
somal loci was performed by using primer pairs and cycling conditions previously reported for phoP,
phoQ, pmrA, and pmrB (21) or for mgrB (19). PCR amplicons were visualized by gel electrophoresis,
and the nucleotide sequences determined were compared to those of K. pneumoniae reference
strains of the same sequence type to identify mutations/disruptions. The status of phoP/phoQ,
pmrA/pmrB, and mgrB maintained by the 10 MDR K. pneumoniae isolates from Pakistan was also
examined by using available draft whole-genome sequences available under accession numbers
MAGC00000000 and MAGE00000000-MAGM00000000 (20). The genome of K. pneumoniae HS11286 was
used for comparison (39). Where appropriate, the absence of mcr variants was conﬁrmed on assembled
genomes with CLC Genomics Workbench 9.5.4 by using the reference sequences NG_050417.1 (mcr-1),
NG_051171.1 (mcr-2), and KX236309 (mcr-1.2). Insertion sequences were identiﬁed with ISﬁnder (40). For
K. pneumoniae isolate BL849, no mgrB sequence or ﬂanking regions could be identiﬁed by either in silico
PCR or read mapping.
Statistical analysis. Statistical analysis and graphing were performed with GraphPad Prism 7
software; a P value of 0.05 was considered signiﬁcant. Statistically signiﬁcant differences among
treatment groups were determined by one-way analysis of variance with Bonferroni’s multiple-
comparison test or, when only two groups were experimentally assayed, an unpaired Student’s t test. The
EC50 of CXCL10-mediated bactericidal activity was determined by using the sigmoidal dose-response
equation of nonlinear regression and is presented as the EC50 and the 95% conﬁdence interval.
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